Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME
Clin Pharmacol Ther. 2014 95 (6): 644-52

PMID: 24549002 · PMCID: PMC4029857 · DOI:10.1038/clpt.2014.37

MeSH Terms (21)

Antineoplastic Agents, Alkylating Brain Neoplasms Cell Line, Tumor Child Cohort Studies Cyclohexylamines Cyclophosphamide Disease-Free Survival Drug Resistance, Neoplasm Genetic Predisposition to Disease Genetic Variation Genome-Wide Association Study Humans Neuroblastoma Phenotype Polymorphism, Single Nucleotide Quality Control Real-Time Polymerase Chain Reaction Risk Assessment RNA, Small Interfering Treatment Failure

Connections (2)

This publication is referenced by other Labnodes entities: